The New England Journal of Medicine recently published the results of a randomized controlled clinical trial that reaffirms the estimated effectiveness of Beyfortus™ (nirsevimab), a second-generation monoclonal antibody that reduces the risk of hospitalization for respiratory syncytial virus (RSV)- associated bronchiolitis in infants by 83%.
This finding is significant since RSV is the leading cause of bronchiolitis, resulting in about three million hospitalizations each year worldwide.
Read More
